Chair at Smart & Biggar
Daphne Lainson is a partner at Smart & Biggar’s Ottawa office and chair of the firm. She specialises in securing patent protection for chemical, pharmaceutical and biotechnology-related inventions. She is a qualified lawyer and patent and trademark agent, and holds an advanced degree in chemistry. She has been helping clients secure patent protection for their innovations for almost two decades and plays a leading role in client relations management within the firm, particularly in key industrial markets like the United States, Japan and Germany.
Ms Lainson champions and safeguards her clients’ IP rights, protecting their inventions in new drugs, biologics, medical devices, consumer products, agrochemicals, specialty chemicals, industrial chemical processes, oil, gas and petrochemicals. She also advises clients on pharmaceutical regulatory law. This includes providing strategic advice during patent prosecution and following patent grant for both pharmaceuticals and biologics. She is called on to advise innovative pharmaceutical and biopharmaceutical companies in matters relating to regulatory data exclusivity under the Food and Drug Regulations, patent listing and enforcement under the Patented Medicines (Notice of Compliance) Regulations, certificates of supplementary protection (CSPs) under the CSP Regulations and market access issues, including those relating to the Patented Medicine Prices Review Board.
Ms Lainson was recognised in the 2017 edition of Euromoney’s Expert Guides (Women in Business Law) as a top legal practitioner in patents. She is named annually as a World IP Review Leader and recognised by Best Lawyers in Canada for IP law and biotechnology law. In 2012 Ms Lainson was listed as one of Canada’s Rising Stars: Leading Lawyers Under 40 by Lexpert and was named Ottawa Businesswoman of the Year 2011 in the professional category by the Women’s Business Network of Ottawa.
Ms Lainson is a fellow of the American Intellectual Property Law Association (AIPLA) and chair of the AIPLA Food and Drug Law Committee.